Bifogade filer
Significant technical progress in the AcouSome project â two novel patent applications filed
Kurs
-1,89%
Likviditet
0,18 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-25 | 06:00 | Bokslutskommuniké 2025 |
| 2025-11-26 | 06:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | 06:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-19 | N/A | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2025-06-18 | N/A | à rsstÀmma |
| 2025-05-28 | 06:00 | Kvartalsrapport 2025-Q1 |
| 2025-04-09 | - | Extra BolagsstÀmma 2025 |
| 2025-02-14 | - | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-02 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2024-04-30 | - | à rsstÀmma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-07 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-26 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2023-04-25 | - | à rsstÀmma |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-18 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-28 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2022-04-27 | - | à rsstÀmma |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-12-21 | - | Extra BolagsstÀmma 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-28 | - | à rsstÀmma |
| 2021-04-15 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-25 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-10 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2020-06-09 | - | à rsstÀmma |
| 2020-05-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-25 | - | Bokslutskommuniké 2019 |
| 2019-11-20 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-18 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2019-06-17 | - | à rsstÀmma |
| 2019-05-22 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-14 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2018-06-13 | - | à rsstÀmma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-21 | - | Extra BolagsstÀmma 2018 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-19 | - | X-dag ordinarie utdelning ACOU 0.00 SEK |
| 2017-06-16 | - | à rsstÀmma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-25 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | HÀlsovÄrd |
| Industri | Bioteknik |
In August 2022, the European Innovation Council (EIC) awarded the AcouSort project AcouSome SEK 26 million to develop groundbreaking technology enabling exosome-based diagnostics. The aim of the project is to develop a low cost acoustofluidic thin film actuated chip for separation of extracellular vesicles from blood. Started in the beginning of 2023, the innovation project has already made significant technical progress resulting in two novel patent applications.
Extracellular vesicles are nanoparticles that enable human cells to communicate vital information with each other. These particles have the potential to open a completely new field within diagnostics, as they are predicted to enable early âstatus reportsâ on organs such as the brain and heart, as well as provide vital information on tumor diseases, infectious diseases, pregnancy, and other health conditions.
Of the SEK 26 million granted by the EIC, SEK 12.2 million goes directly to AcouSort, and the remainder of the funding is distributed to AcouSortâs partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU.
âThe AcouSome project is an innovation project with potential to contribute to the creation of a completely new field within diagnostics. One year into the project, I am happy to report that we have made significant technical progress, and that we are well placed to exploit our technological achievements for our acoustofluidics separation modules in general, but also for achieving our ultimate objective of developing a robust and cost-effective solution for extracellular vesicle separation,â says Torsten Freltoft, AcouSortâs CEO.
FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing â so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The companyâs Certified Adviser is Carnegie Investment Bank AB (publ).